49results about How to "Reduce reperfusion injury" patented technology

A method and apparatus for the prevention and treatment of reperfusion injury following the reperfusion of acute MI which includes modulation of coronary blood flow or oxygen delivery following the reperfusion of the infarct with a catheter placed in the coronary artery or vein.

A method and apparatus for retroperfusing cerebral venous vasculature with autologous venous blood through a percutaneous entry site which incorporates a double-lumen catheter, a self-inflating pressure-regulated balloon mounted on the catheter and a perfusion outflow region either distal to the balloon for direct perfusion into the superior sagittal sinus, or proximal to the balloon for perfusion into the transverse sinus near the junction of the superior sagittal sinus.

A system and method in accordance with the present invention provides a infusion catheter that is flexible, has such a smooth traction and a low profile to minimize break up of the obstruction when crossing it, can access distal vasculature quickly, is easy to use and readily to be implemented in the conventional PCI. Another object is to provide a method that can be performed within a short period of time and employs the catheter described herein to infuse a therapeutic agent distally to the obstruction before it is removed as a means of reducing reperfusion injury, protecting distal vasculature and microcirculation, preserving myocytes, reducing infarct size and ischemic damages in the heart, brain, lung, liver, kidney and limb. Another object is to provide complementary feature options to the infusion catheter and the aspiration catheter to improve the speed and quality of the vessel clearance.

The present embodiments relate to methods for the prevention and treatment of inflammatory conditions such as alcoholic liver disease (ALD). More specifically the present embodiments relate to the prevention and treatment of ALD through the administration of an Retinoic Acid Receptor (RAR) agonist. Some embodiments relate to use of tazarotene in the prevention and treatment of alcohol-induced liver injury, alcohol-related liver disease, fatty liver disease, hepatic steatosis, alcoholic hepatitis or alcoholic cirrhosis.

A method of reducing reperfusion injury in mammalian tissue comprising contacting the tissue with a protein phosphatase 2A (PP2A) inhibitor having the structure:

Implantable medical devices may be utilized to locally delivery one or more drugs or therapeutic agents to treat a wide variety of conditions, including the treatment of the biological organism's reaction to the introduction of the implantable medical device. These therapeutic agents may be released under controlled and directional conditions so that the one or more therapeutic agents reach the correct target area, for example, the surrounding tissue and/or the bloodstream.

A method of treatment of cancer with a formulation of liposomally encapsulated glutathione, that is preferably used orally, increases the level of glutathione in tissues in order to prevent and reverse the metabolic changes in cells that results in the formation of the metabolic “fuel supply” that supports cancer cells, and without which the cells can die out. The method prevents the oxidative stress that damages normal support cells such as stromal fibroblast cells. By blocking the “fuel supply,” the invention can protect, prevent and reverse these cells from the steps of autophagy and mitophagy, that results in the cells decreasing the normal production of ATP for energy and using aerobic glycolysis for energy production. The use of oral liposomally encapsulated glutathione will maintain the presence and normal function of caveolin in fibroblast and other cells, thus preventing their conversion to autophagic tumor stromal cells.

The present invention relates to the therapeutic and prophylactic use of C1 inhibitor for preventing, reducing and treating ischemia and reperfusion injury. The C1 inhibitor of the present invention is still therapeutically effective when administered after an ischemic period and reperfusion and therefore particularly useful for unforeseen occurrences of ischemic reperfusion such as e.g. a stroke.

The invention discloses a medicine compound for treating myocardial ischemia reperfusion of a rat, belonging to the technical field of the medicine compound for preventing and controlling myocardial infarction. The medicine compound for treating myocardial ischemia reperfusion of the rat comprises the following ingredients: 5-15 parts of astragalus extract, 5-10 parts of salvia miltiorrhiza, 2-5 parts of carthamus tinctorius, 1-3 parts of rhodiola rosea, 0.25-0.75 part of procyanidine, 0.25-0.75 part of adiponectin and 1-2 parts of puerarin. According to the medicine compound for treating myocardial ischemia reperfusion of the rat and an application method thereof provided by the invention, the myocardial ischemia reperfusion injury can be obviously relieved; procyanidine which has the effect of relieving inflammation and oxidative stress is added into the medicine compound, so that the oxidation resistance of a body can be promoted; adiponectin has the functions of regulating glucolipid metabolism, resisting inflammation and resisting atherosclerosis; the medicine compound has the function of protecting rat myocardium; the medicine compound can greatly reduce the apoptosis rate of the cells and protect the complete form of the cells.

The invention provides a myocardial-cell-derived exosome based on Tongxinluo pretreatment and a preparation method thereof. The preparation method comprises: pretreating myocardial cells with Tongxinluo, subjecting the pretreated myocardial cells to hypoxia/reoxygenation, and collecting an exosome secreted by the myocardial cells. The myocardial-cell-derived exosome effective in reducing the apoptosis of myocardial microvascular endothelial cells to alleviate myocardial Ischemia reperfusion injury can be prepared via the preparation method.

The invention relates to a pharmaceutical composition comprising a protein phosphatase 2A (PP2A) inhibitor and monosodium glutamate.

The invention discloses a kidney-tonifying traditional Chinese medicine composition for treating ischemic brain injury and a preparation method thereof, relates to the field of traditional Chinese medicines, and aims to solve the problems of poor treatment effect and single treatment mode of a traditional Chinese medicine for treating cerebral ischemic diseases by tonifying kidney and promoting brain circulation. The composition consists of radix rehmanniae preparata, fructus corni, fructus lycii, semen cuscutae, tortoise-plastron glue, rhizoma chuanxiong, ginseng, herba epimedii, poria cocosand herba cistanche, is combined with a traditional Chinese medicine fumigant and an auricular point patch for use, and has a remarkable curative effect on cerebral ischemic diseases. The compositionis applied to the field of brain injury treatment.

The invention relates to the field of medical equipment and provides a flow-limiting external vascular stent. The stent made of an insoluble and non-degradable biocompatible material is of a tubular structure, and an opening for embedding of a blood vessel is axially formed in a stent wall. Due to the fact that the effective inner diameter of the hollow tubular structure of the stent is smaller than the effective outer diameter of the blood vessel which is embedded in the inner wall of the tubular structure from an open-lap seam, compression of the external blood vessel stent upon the blood vessel is formed to reduce the outer diameter of the blood vessel and compress the blood vessel to reduce the inner diameter, and the corresponding treatment purpose is achieved by reducing blood supply of the blood vessel to tissue.

The invention discloses an application of glucogalactooligosaccharide in preparation of a medicine for treating and/or preventing ischemia-reperfusion injury. The glucogalactooligosaccharide disclosed by the invention can be used for remarkably relieving postoperative liver injury, kidney injury, brain injury and the like of ischemia reperfusion mice, is safe and non-toxic, has a strong drug effect, and has a very good medicinal prospect in prevention and treatment of ischemia reperfusion injury.

The invention relates to an oral sustained-release solid preparation with vinpocetine as an active ingredient. It is an oral sustained-release solid preparation made from vinpocetine and its salts and pharmaceutically acceptable auxiliary materials through preparation technology. The oral sustained-release solid preparations involved in the present invention include but not limited to tablets, capsules, granules and sustained-release pellets. The quality is stable, controllable, safe and effective.

The present invention relates to methods and pharmaceutical compositions for cardioprotection of subjects who experienced a myocardial infarction. In particular, the present invention relates to a ligand of the sonic hedgehog signaling pathway for use in the cardioprotection of a subject who experienced a myocardial infarction.

The present invention provides methods for the inhibition of reperfusion injury by treatment with Grammastola spatulata mechanotoxin4 (GsMTx4). The GsMTx4 may be delivered to the ischemic tissue in an individual by any means prior to, during or after ischemia reperfusion injury.

The invention provides a fusion protein TNB with effects of thrombolysis and cerebral protection and coding genes and application of the fusion protein, and discloses a fusion protein with dual effects of thrombolysis and neuroprotection and coding genes and application of the fusion protein. The amino acid sequence of the fusion protein is shown in SEQ ID No. 2. In addition, the invention also discloses nucleotide sequences which are used for encoding the fusion protein, and a preferable nucleotide sequence is shown in SEQ ID No. 4. The pharmacological activity of the fusion protein is evaluated by using a rat arteriovenous bypass thrombolysis model and an embolization model of an artery in a mouse thromboembolic brain, and it is shown that the fusion protein has a good thrombolytic effect and a function of reduction of ischemic brain injuries. A new technology is provided for treatment of acute ischemic stroke and other thrombotic diseases, and the fusion protein has broad application prospects.